Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Fiscal 2024 total sales for the joint venture were approximately $190 million
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Medway setup a state-of-the-art Heart Institute in Chennai
Fischer Chemic will make an entry into the growing market of diagnostic imaging industry with innovative and disruptive technologies
Hospital joins with Intuitive to install da Vinci systems to support enhanced healthcare delivery and patient outcomes across India
Subscribe To Our Newsletter & Stay Updated